NASDAQ:MRSN Mersana Therapeutics Q4 2024 Earnings Report $0.35 +0.02 (+5.63%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.35 -0.01 (-2.17%) As of 04/17/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Mersana Therapeutics EPS ResultsActual EPS-$0.11Consensus EPS -$0.16Beat/MissBeat by +$0.05One Year Ago EPSN/AMersana Therapeutics Revenue ResultsActual Revenue$16.36 millionExpected Revenue$7.71 millionBeat/MissBeat by +$8.65 millionYoY Revenue GrowthN/AMersana Therapeutics Announcement DetailsQuarterQ4 2024Date3/3/2025TimeBefore Market OpensConference Call DateMonday, March 3, 2025Conference Call Time8:00AM ETUpcoming EarningsMersana Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Mersana Therapeutics Q4 2024 Earnings Call TranscriptProvided by QuartrMarch 3, 2025 ShareLink copied to clipboard.There are 11 speakers on the call. Operator00:00:00Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End twenty twenty four Conference Call. Currently, all participants are in a listen only mode. There will be a question and answer session at the end of this call. I would now like to turn the conference over to Jason Fredett, Senior Vice President, Investor Relations and Corporate Communications. Please proceed. Speaker 100:00:26Thank you, operator, and good morning, everyone. Before we begin, please note that this call will contain forward looking statements within the meaning of federal securities laws. These statements may include, but are not limited to, those related to the potential clinical benefits of our product candidates and platforms, our clinical trial progress and designs, dosing and patient management strategies, addressable market opportunities, anticipated milestones and data disclosures and cash runway. Each of these forward looking statements is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements. These risks and uncertainties are discussed in our quarterly report on Form 10 Q filed with the Securities and Exchange Commission on 11/13/2024, and in subsequent SEC filings. Speaker 100:01:14Our filings are available at sec.gov and on our website, mersana.com. Except as required by law, we assume no obligation to update forward looking statements publicly, even if new information becomes available in the future. On today's call, we have Mersana's Chief Executive Officer, Doctor. Marty Huber and our Chief Operating Officer and Chief Financial Officer, Brian De Scheitner. With that, let me turn the call over to Marty to begin the discussion. Speaker 200:01:44Thank you, Jason, and good morning, everyone. Over the past several months, we have accomplished a great deal here at Mersana. Most notably, with our lead dolacinth and ADC, EMILY, we reported positive initial clinical data, started the expansion portion of our Phase one trial and were granted an additional Fast Track designation for a growing portion of the breast cancer population that has previously been treated with a topoisomerase one inhibitor or TOPO1 ADC. At the same time, we advanced Phase one dose escalation with XMT-two thousand and fifty six, our lead immunosynthon ADC, while also supporting our collaborators. Let's focus first on Emily, Mersana's ADC targeting B7H4. Speaker 200:02:29In January, we reported initial clinical data from one hundred and thirty patients who were enrolled in dose escalation and backfill cohorts as of 12/13/2024 data cutoff. From a safety and tolerability standpoint, Emily was observed to be highly differentiated within the ADC space. The most common treatment related adverse events of any grade were transient increases in AST, generally asymptomatic and reversible proteinuria, generally low grade nausea and low grade fatigue. Importantly, unlike many other ADCs, we did not see dose limiting neutropenia, neuropathy, ocular toxicity, interstitial lung disease or thrombocytopenia. This provides us with the confidence that Emily could have an attractive monotherapy profile. Speaker 200:03:16Just as importantly, we believe it also could enable combinations with standards of care like platinum chemotherapy and other ADCs that our competitors would be challenged to pursue. From a clinical activity standpoint, confirmed objective responses were observed in all enrolled tumor types. These included patients with triple negative and hormone receptor positive breast cancer, endometrial cancer, ovarian cancer, and adenoid cystic carcinoma type one, otherwise known as ACC1. At intermediate doses, which range from about thirty eight to sixty seven milligrams per meter squared or about one to two milligrams per kilogram, the confirmed objective response rate was twenty three percent across all tumor types with high B7H4 expression, which we defined as an IHC score of seventy percent or more. Focusing specifically on the evaluable patients in this dose range with B7 H4 high triple negative breast cancer, the confirmed ORR was also twenty three percent. Speaker 200:04:17At the end of twenty twenty four, we initiated the expansion portion of our trial in patients with TNBC who have previously been treated with at least one topo one ABC, a population with a very high unmet need. We believe we are positioned for success for a few key reasons. The first is the dose we're utilizing, the second is our inclusion criteria, third is the standard of care for these patients today, and the final factor is the competitive environment in which we are operating. Let's begin with the dose. Generally speaking, as you might expect, we have seen that clinical activity tends to increase along with Emily's dose. Speaker 200:04:55As I mentioned, the 23% ORR we observed was generated across a range of doses from about thirty eight to sixty seven milligrams per meter squared. We have brought the top dose from this range, specifically sixty seven point four milligrams per meter squared every four weeks, into expansion. As we previously reported, this particular dose was well tolerated. Additionally, each of the four B7H4 Hi patients who received this dose achieved target lesion reductions and each also remained on treatment for durations of approximately sixteen weeks or more as of the data cutoff. A second factor that can influence response is prior treatment. Speaker 200:05:36This is well established in oncology and specifically in triple negative breast cancer. As a reminder, the twenty three percent ORR that we observed with Emily and TNBC was generated in a population of 13 evaluable patients. Twelve of these patients received more than three lines of prior therapy, and all had received at least one TOPO one ADC. These data compare favorably to historical benchmarks. For instance, a twenty three percent ORR was also seen with TRIDELBY and TNBC patients who received more than three prior lines of therapy in the Phase three ASENT study. Speaker 200:06:13But of course, this was in a topo naive setting. TRIDELBI's ORR increased to nearly forty percent in patients who received only two or three prior lines of therapy. In expansion, we are limiting enrollment to patients with a maximum of four prior lines while also mandating that at least one prior treatment must have been a topo 180 C. It is also important to keep in mind what the standard of care is in TNBC today. In Ascent, the control arm, which was single agent chemo, had an ORR of only about 5%. Speaker 200:06:48And finally, there is the competitive environment. We view recent developments within the B7 H4 ADC landscape as favorable for Emily. Most notably, the company that we have viewed as our primary would be competitive within the breast cancer space, Pfizer, recently announced that it had discontinued development of its B7H4 ADC candidate. The other B7 H4 ADCs that are at a similar stage of clinical development as us all have TOPA1 payloads. As a result, unlike Emily, we believe they are subject to TOPA1 resistance mechanisms. Speaker 200:07:22In fact, some of these companies appear to be excluding patients who have received prior TOPO1 therapies from their clinical trials. This positions Emily as the most advanced orostatin ADC in the class, which provides us with a significant opportunity in breast cancer. We are pleased with the level of investigator interest and engagement we are seeing. And while TNBC is our immediate focus, given the clinical activity we have seen across all tumor types, we are excited by Emily's potential in other indications as well. And so enrollment continues at our initial expansion dose of sixty seven point four milligrams per meter squared. Speaker 200:08:00We also continue in to investigate doses up to ninety five milligrams per meter squared in escalation of backfill cohorts delays, we're pleased to report that we officially amended our clinical trial protocol in late January as we seek to mitigate the proteinuria related dose that we were seeing at high doses. We expect these efforts will help us identify a second dose for our second expansion cohort in post TOPA1 TNBC later this year, and we plan to present additional data from dose escalation and backfill later this year as well. Moving on to other areas, we also have advanced the dose escalation portion of our Phase I clinical trial of XMT2056 in recent months. Two thousand and fifty six is our immunosystent and STING agonist ADC targeting a novel epitope or HER2. Later in 2025, we plan to present initial pharmacodynamic data from this clinical trial that helps to characterize this candidate's ability to selectively activate the STING pathway in HER2 expressing tumors. Speaker 200:09:03And finally, I would like to note that we continue to make solid progress in our dolasintin research collaboration with J and J and our immunosyntin research collaboration with Merck KGa. With that, let's turn things over to Brian for some color on our financials. Speaker 300:09:20Thank you, Marty. Beginning with our balance sheet, we ended 2024 with $134,600,000 in cash, cash equivalents and marketable securities. We continue to expect that our capital resources will support our current operating plan commitments into 2026. Please note that our cash runway guidance does not assume any future milestone payments that we may earn from our current collaborations or proceeds that we may realize from future collaborations. Net cash used in operating activities for the fourth quarter of twenty twenty four was $19,300,000 which is down significantly from $32,000,000 in net cash used in operating activities during the year ago quarter. Speaker 300:09:58This decrease primarily reflects our portfolio reprioritization efforts, including the OpEx reductions we implemented in the second half of twenty twenty three as part of our restructuring. Turning to our income statement, collaboration revenue for the fourth quarter of twenty twenty four was $16,400,000 compared to $10,700,000 for the same period in 2023. The year over year change was primarily related to increased collaboration revenue recognized under our agreements with J and J, Merck KJAA and GSK. Research and development expenses for the fourth quarter of twenty twenty four were $22,300,000 compared to $21,500,000 for the same period in 2023. For the most recent quarter, approximately $1,700,000 of this spending was related to non cash stock based compensation. Speaker 300:10:43The year over year change was primarily related to increased costs associated with manufacturing and clinical development activities for Amelie and XMT two thousand and fifty six, which were partially offset by reduced costs related to clinical development activities for our discontinued candidate, UPREIT. General and administrative expenses for the fourth quarter of twenty twenty four declined to $8,900,000 compared to $10,100,000 during the same period in 2023. Approximately $1,700,000 in non cash stock based compensation expenses were included in G and A for the most recent quarter. The year over year decline was primarily related to reduced employee compensation expenses following our restructuring in 2023 and reduced consulting and professional services fees. And finally, Mersana's net loss for the fourth quarter of twenty twenty four was $14,100,000 compared to a net loss of $19,500,000 for the same period in 2023. Speaker 300:11:36That concludes our business update. Operator, would you please open the call to questions from the audience? Operator00:11:44We will now begin the question and answer session. The first question today comes from Jonathan Chang with Leerink Partners. Please go ahead. Speaker 400:12:21Hi. This is Yander Li on for Jonathan Chang. Thanks for taking my question. So the first question I have is that could you share the latest progress on how you are mitigating the ASD LT elevation and proteinuria issue related to Emily? And how do you think that might increase your confidence in maintaining the dose intensity at a higher dose level? Speaker 400:12:45Thank you. Speaker 500:12:49Thank you for the question. I'll start with the AST then going to the proteinuria and then get your last question. So with regards to AST, AST does not result in meaningful amounts of dose delays. And even if a patient does have a delay, it's only about a week. So, at this point in time, AST is a transient reversible phenomena that is not having a meaningful impact on our ability to deliver dose. Speaker 500:13:18With regards to proteinuria, just to reiterate, that is primarily a challenge or leading to dose delays only at the highest dose range. So what we're currently doing is, as we mentioned, we've had an amendment to the protocol, which does several things. One, it puts in place mitigation such as ACE inhibitors and ARBs early in a kind of a prophylactic manner to minimize development of proteinuria. But importantly, as in the setting of when proteinuria does occur, but it is asymptomatic in that a patient is not having edema, not having they're not having any serum hypoalbuminemia or serum creatinine changes, for those patients, we're able to maintain dosing by doing a dose reduction as opposed to a dose delay. So we are we look forward to testing that in the clinic to show that we are able to maintain dose intensity. Speaker 500:14:20But the clinical outcome will I mean, we're doing the experiment now. Speaker 400:14:27Got it. And just a quick follow-up on the proteinuria. I think on the separate code, you did mention that it was related to podocytopathy. And do you think that's caused by B7H4 on target or off target? Just curious about the mechanism. Speaker 400:14:45Thank you. Speaker 500:14:46We don't at this point in time, we believe it is off target. Other oracatin payloads that are not for B7H4 have been observed to have albuminuria, the same type of podocyte effect. Operator00:15:07The next question comes from Charles Hsu with LifeSci Capital. Please go ahead. Speaker 600:15:14Hey, good morning, everyone. Thanks for taking our questions for the call and hope everyone had a great weekend. Regarding your dose expansion criteria of having patients with one to four prior lines of therapy, what's your sense of the distribution of patients that you might be getting that have fewer, call it, one to two as opposed to more, call it, three to four prior lines of a therapy? Thank you. Speaker 500:15:38I think it's too early to get that read. I mean, we opened it in the study and we're still gathering data. So I think it would be premature for me to give guidance on what we think are the lines that are actually going to be in the population. One thing we can clearly say is per inclusion exclusion criteria, those patients who had previously been on with five, six or seven are excluded from expansion. So at a minimum, it will ensure that patients don't have more than four prior lines. Speaker 500:16:12That is part of the protocol. Speaker 600:16:16Got it. Great. Thank you for that. Maybe one quick follow-up right now. I guess then, you know, like, I think you went through this a little bit as well, but to what extent will your second dose, your second go forward dose, the identification of that be dependent on your ability to mitigate proteinuria? Speaker 600:16:41So you've already selected sixty seven point three in the intermediate range. And is there a scenario where you go for something, let's call it in the middle to the higher end of your high dose range if your protein urea mitigation works very well? Or is there an alternative scenario where you could end up maybe selecting even a separate dose beyond that? Thank you. Speaker 500:17:07At this point in time, we are setting doses up to ninety five milligrams per meter squared. We are so we are not exploring anything higher than that at this point in time. Speaker 600:17:22Got it. Thank you for taking the questions. Operator00:17:33The next question comes from Michael Schmidt with Guggenheim. Please go ahead. Speaker 700:17:39Hey, good morning. Speaker 800:17:40Thanks for taking our questions. This is Paul on for Michael. I wanted to expand a bit on how you're currently thinking about establishing the final biomarker cutoff. Is it reasonable to expect where you land on TPS score to still capture roughly half of the TNBC population? Or could there still be a meaningful swing factor in how you're thinking about B7H4 high? Speaker 500:18:02I think while we continue to explore it, I would be surprised if it's outside of that 40% to 50% at the upper limit is most likely where we'll end up. It would be to me, it would be very surprising if we end up with more than 50% or substantially less than 40. But and with the I'm sorry, for percent of for a proportion of the population, the TPS score could be best TDD with the actual percent TPS tumor proportion score number is. Speaker 800:18:42Got it. And then just as a follow-up, just can you set some expectations for the updated Phase one dose escalation and backfill data later this year, which dose levels are in focus for enrollment, how many additional patients of data can we potentially see and what's the sort of gating factor for when you'll be ready to provide that update? Thank you. Speaker 700:19:01Yes. This is Jason. We haven't defined that. What we've said is we plan to present additional escalation and backfill data later on this year as Marty alluded to. We're looking at doses up to ninety five midds per meter squared, but we haven't defined how much incremental data would be in that readout. Operator00:19:33The next question comes from Andy Hsieh with William Blair. Please go ahead. Speaker 800:19:40Great. Thanks for taking our questions. Just one quick one for us. Just looking at the updated deck, I think the only thing that changed is the competitive landscape. Marty, I think you've mentioned a little bit in your prepared remarks about the evolving competitive landscape. Speaker 800:19:55But I'm curious if you can kind of dive in deeper about some of the competitors that went to Phase three, dropped out, just Thank you. Yes. Speaker 500:20:07I'm going to let Brian give you a more detailed answer on that one. Speaker 900:20:10Yes. As Marty articulated, we believe that Emily is very well positioned in the B7H4 space. As you noted with the departure of one of our competitors, we're the most advanced for statin B7H4 in development. We're the only company that has shared initial positive efficacy data in that post topo breast cancer setting. As you remark, one competitor is moving into pivotal studies in a gynecologic tumor. Speaker 900:20:38I think we feel like this is very encouraging because it's an additional validation that you can see meaningful activity on that target. But several topo competitors very much focused on ovarian and endometrial at this stage. So we believe, one, in Emily's potential as monotherapy. We also believe that our safety and tolerability profile may afford us an opportunity to combine with things like platinum chemo and other ADCs. And we think long term as a set of development opportunities, some of our competitors might be very challenged to pursue those combinations. Speaker 900:21:17And so I think as we look at the overall competitive landscape, we view it very favorably. Operator00:21:31The next question comes from Asthika Goonewardene with Truist. Please go ahead. Speaker 900:21:39Hey, good morning guys. Thanks for taking my questions. Two quick ones, if I may. Could you give us a little bit of clarity on when we could expect some of the expansion cohort data up to sixty seven mgs? And then when you presented data early this year, we looked at three different intervals, the Q3, the Q4 and then a two on, two off. Speaker 900:22:00I'm curious if you're looking at other intervals maybe like a three on, one off or any other types of other formats as well just to kind of set up the clutch on the dosing? Thank you. Speaker 500:22:11This is Marty. I'll answer the second one first. At this point in time, we are not studying any schedules beyond what we previously shared. We are continuing to explore different schedules at this point in time, but they're limited to the three we've already shared. And with regards to expansion, we are not giving any further details on timing of expansion other than to say that we are continuing to enroll patients and investigators remain enthusiastic about the study. Operator00:22:53The next question comes from Colleen Cusi with Baird. Please go ahead. Speaker 500:23:00Hey, all. This is Nick on for Collyn. Thanks for taking our question. So for XMT two thousand and fifty six, just wanted to ask what you have to show on the PD update and if there's a ballpark on how many patients or how much follow-up you might have and if we can might see any early efficacy data at that time as well? Thanks. Speaker 500:23:20We're not going into any detail beyond the fact that our primary objective will be to share pharmacodynamic data showing that we're getting activation of the same pathway in HER2 positive tumors. As far as any other details, we're not sharing at this point in time. Operator00:23:49The next question comes from Justin Zelman with BTIG. Please go ahead. Speaker 1000:23:56Great. Thanks for taking the question. This is Jeet on for Justin. I believe you had said you're going up to ninety five mgs per meter squared, but I do believe there was a one hundred and fifteen mg dose. Was there any reason why one hundred and fifteen mgs isn't being explored further? Speaker 1000:24:09And will we see a meaningful number of patients with proteinuria mitigation as part of this year's update? Speaker 500:24:17Well, I think well, first of all, we are not studying 115 any further. At the 115, we did observe the we saw it was reversible, but we did see grade three ASC in two of the three patients. And while we could have potentially explored that further, we made the decision that we were not going to because we were getting the exposures we were targeting at ninety five and below. So our focus has been on a cap of the ninety five every four weeks or the variations of that. Speaker 700:24:50And on the second question, in terms of, again, the additional escalation and backfill data. What we'll show is somewhat time dependent, right, in terms of when we plan to share data. So we're not providing any additional specifics at this stage. Speaker 1000:25:11Got it. And maybe a follow-up. With the Pfizer program now discontinued, have you spoken to any KOLs who have been on both the Pfizer study as well as yours? And if so, how do they compare the Speaker 800:25:21two agents so far? Thank you. Speaker 500:25:24Well, they're not going to give us details of confidential data from Pfizer. I think the main thing has been, at this point in time, we had already heard from the investigators and the KOLs that Pfizer was not going to pursue their B7H4 ENT and B2 post TOPA. That was known even before they discontinued the program overall. And so we were being approached by investigators to participate in our study because they have if they when they basically heard through the grapevine, to be frank, even before our data was disclosed, because we meet with these investigators, we have them under CDAs, they looked at our data as a promising opportunity at TMBC post topo. And to be frank, it was the only game in town for their patients. Speaker 500:26:18So, that's why we had several of those sites actively decide to join our study. As far as the actual data that Pfizer had in this population, they did not share that with us other than once again other than to state that Pfizer was not pursuing this indication. Operator00:26:41This concludes our question and answer session. I would like to turn the conference back over to CEO, Doctor. Marty Huber, for any closing remarks. Speaker 500:26:50Thank you, operator, and thanks everyone for dialing in. We look forward to seeing many of you at the TD Cowen Healthcare Conference here in Boston tomorrow as well as at Lyrics Healthcare Conference in Miami next week. That concludes our call, operator. Thank you. Operator00:27:05The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallMersana Therapeutics Q4 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Annual report(10-K) Mersana Therapeutics Earnings HeadlinesMersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual CongressApril 1, 2025 | globenewswire.comMersana at Leerink Global Healthcare Conference: Strategic ADC InsightsMarch 14, 2025 | investing.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 20, 2025 | Porter & Company (Ad)Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their EstimatesMarch 6, 2025 | finance.yahoo.comIndustry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue ForecastsMarch 6, 2025 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | insidermonkey.comSee More Mersana Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mersana Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mersana Therapeutics and other key companies, straight to your email. Email Address About Mersana TherapeuticsMersana Therapeutics (NASDAQ:MRSN), a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.View Mersana Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 11 speakers on the call. Operator00:00:00Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End twenty twenty four Conference Call. Currently, all participants are in a listen only mode. There will be a question and answer session at the end of this call. I would now like to turn the conference over to Jason Fredett, Senior Vice President, Investor Relations and Corporate Communications. Please proceed. Speaker 100:00:26Thank you, operator, and good morning, everyone. Before we begin, please note that this call will contain forward looking statements within the meaning of federal securities laws. These statements may include, but are not limited to, those related to the potential clinical benefits of our product candidates and platforms, our clinical trial progress and designs, dosing and patient management strategies, addressable market opportunities, anticipated milestones and data disclosures and cash runway. Each of these forward looking statements is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements. These risks and uncertainties are discussed in our quarterly report on Form 10 Q filed with the Securities and Exchange Commission on 11/13/2024, and in subsequent SEC filings. Speaker 100:01:14Our filings are available at sec.gov and on our website, mersana.com. Except as required by law, we assume no obligation to update forward looking statements publicly, even if new information becomes available in the future. On today's call, we have Mersana's Chief Executive Officer, Doctor. Marty Huber and our Chief Operating Officer and Chief Financial Officer, Brian De Scheitner. With that, let me turn the call over to Marty to begin the discussion. Speaker 200:01:44Thank you, Jason, and good morning, everyone. Over the past several months, we have accomplished a great deal here at Mersana. Most notably, with our lead dolacinth and ADC, EMILY, we reported positive initial clinical data, started the expansion portion of our Phase one trial and were granted an additional Fast Track designation for a growing portion of the breast cancer population that has previously been treated with a topoisomerase one inhibitor or TOPO1 ADC. At the same time, we advanced Phase one dose escalation with XMT-two thousand and fifty six, our lead immunosynthon ADC, while also supporting our collaborators. Let's focus first on Emily, Mersana's ADC targeting B7H4. Speaker 200:02:29In January, we reported initial clinical data from one hundred and thirty patients who were enrolled in dose escalation and backfill cohorts as of 12/13/2024 data cutoff. From a safety and tolerability standpoint, Emily was observed to be highly differentiated within the ADC space. The most common treatment related adverse events of any grade were transient increases in AST, generally asymptomatic and reversible proteinuria, generally low grade nausea and low grade fatigue. Importantly, unlike many other ADCs, we did not see dose limiting neutropenia, neuropathy, ocular toxicity, interstitial lung disease or thrombocytopenia. This provides us with the confidence that Emily could have an attractive monotherapy profile. Speaker 200:03:16Just as importantly, we believe it also could enable combinations with standards of care like platinum chemotherapy and other ADCs that our competitors would be challenged to pursue. From a clinical activity standpoint, confirmed objective responses were observed in all enrolled tumor types. These included patients with triple negative and hormone receptor positive breast cancer, endometrial cancer, ovarian cancer, and adenoid cystic carcinoma type one, otherwise known as ACC1. At intermediate doses, which range from about thirty eight to sixty seven milligrams per meter squared or about one to two milligrams per kilogram, the confirmed objective response rate was twenty three percent across all tumor types with high B7H4 expression, which we defined as an IHC score of seventy percent or more. Focusing specifically on the evaluable patients in this dose range with B7 H4 high triple negative breast cancer, the confirmed ORR was also twenty three percent. Speaker 200:04:17At the end of twenty twenty four, we initiated the expansion portion of our trial in patients with TNBC who have previously been treated with at least one topo one ABC, a population with a very high unmet need. We believe we are positioned for success for a few key reasons. The first is the dose we're utilizing, the second is our inclusion criteria, third is the standard of care for these patients today, and the final factor is the competitive environment in which we are operating. Let's begin with the dose. Generally speaking, as you might expect, we have seen that clinical activity tends to increase along with Emily's dose. Speaker 200:04:55As I mentioned, the 23% ORR we observed was generated across a range of doses from about thirty eight to sixty seven milligrams per meter squared. We have brought the top dose from this range, specifically sixty seven point four milligrams per meter squared every four weeks, into expansion. As we previously reported, this particular dose was well tolerated. Additionally, each of the four B7H4 Hi patients who received this dose achieved target lesion reductions and each also remained on treatment for durations of approximately sixteen weeks or more as of the data cutoff. A second factor that can influence response is prior treatment. Speaker 200:05:36This is well established in oncology and specifically in triple negative breast cancer. As a reminder, the twenty three percent ORR that we observed with Emily and TNBC was generated in a population of 13 evaluable patients. Twelve of these patients received more than three lines of prior therapy, and all had received at least one TOPO one ADC. These data compare favorably to historical benchmarks. For instance, a twenty three percent ORR was also seen with TRIDELBY and TNBC patients who received more than three prior lines of therapy in the Phase three ASENT study. Speaker 200:06:13But of course, this was in a topo naive setting. TRIDELBI's ORR increased to nearly forty percent in patients who received only two or three prior lines of therapy. In expansion, we are limiting enrollment to patients with a maximum of four prior lines while also mandating that at least one prior treatment must have been a topo 180 C. It is also important to keep in mind what the standard of care is in TNBC today. In Ascent, the control arm, which was single agent chemo, had an ORR of only about 5%. Speaker 200:06:48And finally, there is the competitive environment. We view recent developments within the B7 H4 ADC landscape as favorable for Emily. Most notably, the company that we have viewed as our primary would be competitive within the breast cancer space, Pfizer, recently announced that it had discontinued development of its B7H4 ADC candidate. The other B7 H4 ADCs that are at a similar stage of clinical development as us all have TOPA1 payloads. As a result, unlike Emily, we believe they are subject to TOPA1 resistance mechanisms. Speaker 200:07:22In fact, some of these companies appear to be excluding patients who have received prior TOPO1 therapies from their clinical trials. This positions Emily as the most advanced orostatin ADC in the class, which provides us with a significant opportunity in breast cancer. We are pleased with the level of investigator interest and engagement we are seeing. And while TNBC is our immediate focus, given the clinical activity we have seen across all tumor types, we are excited by Emily's potential in other indications as well. And so enrollment continues at our initial expansion dose of sixty seven point four milligrams per meter squared. Speaker 200:08:00We also continue in to investigate doses up to ninety five milligrams per meter squared in escalation of backfill cohorts delays, we're pleased to report that we officially amended our clinical trial protocol in late January as we seek to mitigate the proteinuria related dose that we were seeing at high doses. We expect these efforts will help us identify a second dose for our second expansion cohort in post TOPA1 TNBC later this year, and we plan to present additional data from dose escalation and backfill later this year as well. Moving on to other areas, we also have advanced the dose escalation portion of our Phase I clinical trial of XMT2056 in recent months. Two thousand and fifty six is our immunosystent and STING agonist ADC targeting a novel epitope or HER2. Later in 2025, we plan to present initial pharmacodynamic data from this clinical trial that helps to characterize this candidate's ability to selectively activate the STING pathway in HER2 expressing tumors. Speaker 200:09:03And finally, I would like to note that we continue to make solid progress in our dolasintin research collaboration with J and J and our immunosyntin research collaboration with Merck KGa. With that, let's turn things over to Brian for some color on our financials. Speaker 300:09:20Thank you, Marty. Beginning with our balance sheet, we ended 2024 with $134,600,000 in cash, cash equivalents and marketable securities. We continue to expect that our capital resources will support our current operating plan commitments into 2026. Please note that our cash runway guidance does not assume any future milestone payments that we may earn from our current collaborations or proceeds that we may realize from future collaborations. Net cash used in operating activities for the fourth quarter of twenty twenty four was $19,300,000 which is down significantly from $32,000,000 in net cash used in operating activities during the year ago quarter. Speaker 300:09:58This decrease primarily reflects our portfolio reprioritization efforts, including the OpEx reductions we implemented in the second half of twenty twenty three as part of our restructuring. Turning to our income statement, collaboration revenue for the fourth quarter of twenty twenty four was $16,400,000 compared to $10,700,000 for the same period in 2023. The year over year change was primarily related to increased collaboration revenue recognized under our agreements with J and J, Merck KJAA and GSK. Research and development expenses for the fourth quarter of twenty twenty four were $22,300,000 compared to $21,500,000 for the same period in 2023. For the most recent quarter, approximately $1,700,000 of this spending was related to non cash stock based compensation. Speaker 300:10:43The year over year change was primarily related to increased costs associated with manufacturing and clinical development activities for Amelie and XMT two thousand and fifty six, which were partially offset by reduced costs related to clinical development activities for our discontinued candidate, UPREIT. General and administrative expenses for the fourth quarter of twenty twenty four declined to $8,900,000 compared to $10,100,000 during the same period in 2023. Approximately $1,700,000 in non cash stock based compensation expenses were included in G and A for the most recent quarter. The year over year decline was primarily related to reduced employee compensation expenses following our restructuring in 2023 and reduced consulting and professional services fees. And finally, Mersana's net loss for the fourth quarter of twenty twenty four was $14,100,000 compared to a net loss of $19,500,000 for the same period in 2023. Speaker 300:11:36That concludes our business update. Operator, would you please open the call to questions from the audience? Operator00:11:44We will now begin the question and answer session. The first question today comes from Jonathan Chang with Leerink Partners. Please go ahead. Speaker 400:12:21Hi. This is Yander Li on for Jonathan Chang. Thanks for taking my question. So the first question I have is that could you share the latest progress on how you are mitigating the ASD LT elevation and proteinuria issue related to Emily? And how do you think that might increase your confidence in maintaining the dose intensity at a higher dose level? Speaker 400:12:45Thank you. Speaker 500:12:49Thank you for the question. I'll start with the AST then going to the proteinuria and then get your last question. So with regards to AST, AST does not result in meaningful amounts of dose delays. And even if a patient does have a delay, it's only about a week. So, at this point in time, AST is a transient reversible phenomena that is not having a meaningful impact on our ability to deliver dose. Speaker 500:13:18With regards to proteinuria, just to reiterate, that is primarily a challenge or leading to dose delays only at the highest dose range. So what we're currently doing is, as we mentioned, we've had an amendment to the protocol, which does several things. One, it puts in place mitigation such as ACE inhibitors and ARBs early in a kind of a prophylactic manner to minimize development of proteinuria. But importantly, as in the setting of when proteinuria does occur, but it is asymptomatic in that a patient is not having edema, not having they're not having any serum hypoalbuminemia or serum creatinine changes, for those patients, we're able to maintain dosing by doing a dose reduction as opposed to a dose delay. So we are we look forward to testing that in the clinic to show that we are able to maintain dose intensity. Speaker 500:14:20But the clinical outcome will I mean, we're doing the experiment now. Speaker 400:14:27Got it. And just a quick follow-up on the proteinuria. I think on the separate code, you did mention that it was related to podocytopathy. And do you think that's caused by B7H4 on target or off target? Just curious about the mechanism. Speaker 400:14:45Thank you. Speaker 500:14:46We don't at this point in time, we believe it is off target. Other oracatin payloads that are not for B7H4 have been observed to have albuminuria, the same type of podocyte effect. Operator00:15:07The next question comes from Charles Hsu with LifeSci Capital. Please go ahead. Speaker 600:15:14Hey, good morning, everyone. Thanks for taking our questions for the call and hope everyone had a great weekend. Regarding your dose expansion criteria of having patients with one to four prior lines of therapy, what's your sense of the distribution of patients that you might be getting that have fewer, call it, one to two as opposed to more, call it, three to four prior lines of a therapy? Thank you. Speaker 500:15:38I think it's too early to get that read. I mean, we opened it in the study and we're still gathering data. So I think it would be premature for me to give guidance on what we think are the lines that are actually going to be in the population. One thing we can clearly say is per inclusion exclusion criteria, those patients who had previously been on with five, six or seven are excluded from expansion. So at a minimum, it will ensure that patients don't have more than four prior lines. Speaker 500:16:12That is part of the protocol. Speaker 600:16:16Got it. Great. Thank you for that. Maybe one quick follow-up right now. I guess then, you know, like, I think you went through this a little bit as well, but to what extent will your second dose, your second go forward dose, the identification of that be dependent on your ability to mitigate proteinuria? Speaker 600:16:41So you've already selected sixty seven point three in the intermediate range. And is there a scenario where you go for something, let's call it in the middle to the higher end of your high dose range if your protein urea mitigation works very well? Or is there an alternative scenario where you could end up maybe selecting even a separate dose beyond that? Thank you. Speaker 500:17:07At this point in time, we are setting doses up to ninety five milligrams per meter squared. We are so we are not exploring anything higher than that at this point in time. Speaker 600:17:22Got it. Thank you for taking the questions. Operator00:17:33The next question comes from Michael Schmidt with Guggenheim. Please go ahead. Speaker 700:17:39Hey, good morning. Speaker 800:17:40Thanks for taking our questions. This is Paul on for Michael. I wanted to expand a bit on how you're currently thinking about establishing the final biomarker cutoff. Is it reasonable to expect where you land on TPS score to still capture roughly half of the TNBC population? Or could there still be a meaningful swing factor in how you're thinking about B7H4 high? Speaker 500:18:02I think while we continue to explore it, I would be surprised if it's outside of that 40% to 50% at the upper limit is most likely where we'll end up. It would be to me, it would be very surprising if we end up with more than 50% or substantially less than 40. But and with the I'm sorry, for percent of for a proportion of the population, the TPS score could be best TDD with the actual percent TPS tumor proportion score number is. Speaker 800:18:42Got it. And then just as a follow-up, just can you set some expectations for the updated Phase one dose escalation and backfill data later this year, which dose levels are in focus for enrollment, how many additional patients of data can we potentially see and what's the sort of gating factor for when you'll be ready to provide that update? Thank you. Speaker 700:19:01Yes. This is Jason. We haven't defined that. What we've said is we plan to present additional escalation and backfill data later on this year as Marty alluded to. We're looking at doses up to ninety five midds per meter squared, but we haven't defined how much incremental data would be in that readout. Operator00:19:33The next question comes from Andy Hsieh with William Blair. Please go ahead. Speaker 800:19:40Great. Thanks for taking our questions. Just one quick one for us. Just looking at the updated deck, I think the only thing that changed is the competitive landscape. Marty, I think you've mentioned a little bit in your prepared remarks about the evolving competitive landscape. Speaker 800:19:55But I'm curious if you can kind of dive in deeper about some of the competitors that went to Phase three, dropped out, just Thank you. Yes. Speaker 500:20:07I'm going to let Brian give you a more detailed answer on that one. Speaker 900:20:10Yes. As Marty articulated, we believe that Emily is very well positioned in the B7H4 space. As you noted with the departure of one of our competitors, we're the most advanced for statin B7H4 in development. We're the only company that has shared initial positive efficacy data in that post topo breast cancer setting. As you remark, one competitor is moving into pivotal studies in a gynecologic tumor. Speaker 900:20:38I think we feel like this is very encouraging because it's an additional validation that you can see meaningful activity on that target. But several topo competitors very much focused on ovarian and endometrial at this stage. So we believe, one, in Emily's potential as monotherapy. We also believe that our safety and tolerability profile may afford us an opportunity to combine with things like platinum chemo and other ADCs. And we think long term as a set of development opportunities, some of our competitors might be very challenged to pursue those combinations. Speaker 900:21:17And so I think as we look at the overall competitive landscape, we view it very favorably. Operator00:21:31The next question comes from Asthika Goonewardene with Truist. Please go ahead. Speaker 900:21:39Hey, good morning guys. Thanks for taking my questions. Two quick ones, if I may. Could you give us a little bit of clarity on when we could expect some of the expansion cohort data up to sixty seven mgs? And then when you presented data early this year, we looked at three different intervals, the Q3, the Q4 and then a two on, two off. Speaker 900:22:00I'm curious if you're looking at other intervals maybe like a three on, one off or any other types of other formats as well just to kind of set up the clutch on the dosing? Thank you. Speaker 500:22:11This is Marty. I'll answer the second one first. At this point in time, we are not studying any schedules beyond what we previously shared. We are continuing to explore different schedules at this point in time, but they're limited to the three we've already shared. And with regards to expansion, we are not giving any further details on timing of expansion other than to say that we are continuing to enroll patients and investigators remain enthusiastic about the study. Operator00:22:53The next question comes from Colleen Cusi with Baird. Please go ahead. Speaker 500:23:00Hey, all. This is Nick on for Collyn. Thanks for taking our question. So for XMT two thousand and fifty six, just wanted to ask what you have to show on the PD update and if there's a ballpark on how many patients or how much follow-up you might have and if we can might see any early efficacy data at that time as well? Thanks. Speaker 500:23:20We're not going into any detail beyond the fact that our primary objective will be to share pharmacodynamic data showing that we're getting activation of the same pathway in HER2 positive tumors. As far as any other details, we're not sharing at this point in time. Operator00:23:49The next question comes from Justin Zelman with BTIG. Please go ahead. Speaker 1000:23:56Great. Thanks for taking the question. This is Jeet on for Justin. I believe you had said you're going up to ninety five mgs per meter squared, but I do believe there was a one hundred and fifteen mg dose. Was there any reason why one hundred and fifteen mgs isn't being explored further? Speaker 1000:24:09And will we see a meaningful number of patients with proteinuria mitigation as part of this year's update? Speaker 500:24:17Well, I think well, first of all, we are not studying 115 any further. At the 115, we did observe the we saw it was reversible, but we did see grade three ASC in two of the three patients. And while we could have potentially explored that further, we made the decision that we were not going to because we were getting the exposures we were targeting at ninety five and below. So our focus has been on a cap of the ninety five every four weeks or the variations of that. Speaker 700:24:50And on the second question, in terms of, again, the additional escalation and backfill data. What we'll show is somewhat time dependent, right, in terms of when we plan to share data. So we're not providing any additional specifics at this stage. Speaker 1000:25:11Got it. And maybe a follow-up. With the Pfizer program now discontinued, have you spoken to any KOLs who have been on both the Pfizer study as well as yours? And if so, how do they compare the Speaker 800:25:21two agents so far? Thank you. Speaker 500:25:24Well, they're not going to give us details of confidential data from Pfizer. I think the main thing has been, at this point in time, we had already heard from the investigators and the KOLs that Pfizer was not going to pursue their B7H4 ENT and B2 post TOPA. That was known even before they discontinued the program overall. And so we were being approached by investigators to participate in our study because they have if they when they basically heard through the grapevine, to be frank, even before our data was disclosed, because we meet with these investigators, we have them under CDAs, they looked at our data as a promising opportunity at TMBC post topo. And to be frank, it was the only game in town for their patients. Speaker 500:26:18So, that's why we had several of those sites actively decide to join our study. As far as the actual data that Pfizer had in this population, they did not share that with us other than once again other than to state that Pfizer was not pursuing this indication. Operator00:26:41This concludes our question and answer session. I would like to turn the conference back over to CEO, Doctor. Marty Huber, for any closing remarks. Speaker 500:26:50Thank you, operator, and thanks everyone for dialing in. We look forward to seeing many of you at the TD Cowen Healthcare Conference here in Boston tomorrow as well as at Lyrics Healthcare Conference in Miami next week. That concludes our call, operator. Thank you. Operator00:27:05The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by